Cover Image
市場調查報告書

持田製藥::產品平台分析

Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 253824
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
持田製藥::產品平台分析 Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014
出版日期: 2014年11月30日 內容資訊: 英文 31 Pages
簡介

持田製藥是透過醫藥·醫療品,醫療設備產業對醫療產業有卓越貢獻的醫療相關企業。該公司產品主要活用於心臟血管,皮膚科,緊急醫療科,婦產科,精神科,不孕治療等領域。

本報告提供持田製藥的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,同時也提供最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

持田製藥的基本資料

持田製藥概要

  • 主要資訊
  • 企業資料

持田製藥:R&D概要

  • 主要的治療範圍

持田製藥:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

持田製藥:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

持田製藥:藥物簡介▼dienogest

  • mesalamine ER
  • icosapent ethyl
  • etanercept biosimilar
  • Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular

持田製藥:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

持田製藥:最近的開發平台趨勢

持田製藥:暫停中的計劃

持田製藥:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • ulinastatin

持田製藥:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06598CDB

Summary

Global Markets Direct's, 'Mochida Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Mochida Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Mochida Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Mochida Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Mochida Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Mochida Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Mochida Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Mochida Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Mochida Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Mochida Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mochida Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Mochida Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Mochida Pharmaceutical Co., Ltd. Snapshot
    • Mochida Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Mochida Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Mochida Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Mochida Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Mochida Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Mochida Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Mochida Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Mochida Pharmaceutical Co., Ltd. - Drug Profiles
    • dienogest
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mesalamine ER
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • icosapent ethyl
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit Elovl-6 for Metabolic Diseases And Cardiovascular
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Mochida Pharmaceutical Co., Ltd. - Pipeline Analysis
    • Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Target
    • Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
    • Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
    • Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Mochida Pharmaceutical Co., Ltd. - Recent Pipeline Updates
  • Mochida Pharmaceutical Co., Ltd. - Dormant Projects
  • Mochida Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ulinastatin
  • Mochida Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Mochida Pharmaceutical Co., Ltd., Key Information
  • Mochida Pharmaceutical Co., Ltd., Key Facts
  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • Mochida Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • Mochida Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014
  • Mochida Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014
  • Mochida Pharmaceutical Co., Ltd. - Phase III, 2014
  • Mochida Pharmaceutical Co., Ltd. - Phase II, 2014
  • Mochida Pharmaceutical Co., Ltd. - Phase I, 2014
  • Mochida Pharmaceutical Co., Ltd. - Preclinical, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Target, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
  • Mochida Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014
  • Mochida Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014
  • Mochida Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014
  • Mochida Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014
  • Mochida Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • Mochida Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • Mochida Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top